Purpose of Review: In this article, we review why patients may fail medical therapy for benign prostatic hyperplasia (BPH) and by doing so, gain a better understanding of the disease process and how to optimize the care of these patients. Recent Findings: A growing body of literature has attempted to better characterize the various mechanisms by which patients develop BPH as well as identify predictors of disease progression and treatment failure. Summary: BPH is a heterogenous disease process. A more personalized approach to treatment, including patient selection for medical or surgical management, would allow us to optimize patient care.
- 5alpha-reductase inhibitors
- Benign prostatic hyperplasia
- Clinical trial results
- Medical therapy
- Predictors of treatment failure